---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-044400"
form_type: "8-K"
ticker: "CMPS"
cik: "0001816590"
company_name: "COMPASS Pathways plc"
filed_at: "2024-10-31T23:59:59+00:00"
generated_at: "2026-05-30T07:37:48.603548+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Compass Pathways delays COMP360 phase 3 data to Q2 2025; workforce reduction of 30%

## Summary
- COMP005 phase 3 top-line data in TRD now expected Q2 2025; COMP006 data shifted to H2 2026 after unblinding risk.
- Workforce reduction of ~30% including senior management roles; non-COMP360 preclinical halted; digital health tools explored for externalization.
- Net loss Q3 2024 $38.5M ($0.56 loss per share) vs $33.4M loss ($0.67 loss per share) in Q3 2023.
- Cash and equivalents $207M as of Sept 30, 2024; projected to fund operations at least into 2026.
- R&D expenses rose to $32.9M in Q3 2024 from $21.5M in Q3 2023, driven by phase 3 clinical costs.

## SEC filing metadata
- accession: 0001628280-24-044400
- form_type: 8-K
- ticker: CMPS
- cik: 0001816590
- company_name: COMPASS Pathways plc
- filed_at: 2024-10-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816590/000162828024044400/0001628280-24-044400-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816590/000162828024044400/cmps-20241031.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-044400
- JSON: https://secwatch.observer/filing/0001628280-24-044400.json
- Plain text: https://secwatch.observer/filing/0001628280-24-044400.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.